Integra LifeSciences Appoints Lea Daniels Knight, Executive Vice President and Chief Financial Officer
21 Junho 2023 - 5:15PM
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today
announced the appointment of Lea Daniels Knight as executive vice
president and chief financial officer, effective June 28, 2023.
Ms. Knight has over 30 years of experience in global companies
with significant operating scale and complexity, leading and
developing high-performing teams, and demonstrating success in
combining financial acumen and business process leadership with
strategic vision to deliver strong business outcomes.
Most recently, she served as the executive vice president of
business finance for Booz Allen Hamilton where she was responsible
for providing strategic and financial leadership to all of the
company’s business sectors to support above-market growth. Prior to
Booz Allen Hamilton, she worked at Johnson & Johnson for 18
years, assuming finance roles with increasing responsibility,
including as chief financial officer of Johnson & Johnson’s
North America pharmaceuticals business. Throughout her tenure at
the company, Ms. Knight helped drive cost optimization initiatives,
manage risk and create innovative solutions across six of the
organization’s operating companies within their consumer,
pharmaceutical and corporate sectors. She started her
career in public accounting at Arthur Andersen LLP where she spent
nine years managing large, technically complex audit engagements
and helped to stand-up the firm’s Healthcare Consulting and Mergers
& Acquisitions practices for the Philadelphia office.
“Lea brings a wealth of finance, accounting, and extensive
healthcare industry experience, and has the necessary capabilities
to successfully partner with me and our executive leadership to
lead change and drive growth and financial outcomes,” said Jan De
Witte, president and chief executive officer, Integra LifeSciences.
“She is passionate about leadership and talent development with
broad experience leading geographically dispersed teams that have
outperformed and created shareholder value.”
“I deeply admire the company’s purpose of restoring patients’
lives and its mission of driving innovation and setting new
treatment standards of care as it aligns with my own values,” said
Ms. Knight. “I look forward to leveraging my experience in finance,
healthcare, global business services and operational organizations,
and build on Integra’s leadership position in surgical, neurologic
and regenerative care to create long-term value for our customers,
patients and shareholders.”
Ms. Knight is a member of the board of trustees for Jefferson
Abington Hospital in Abington, Pa. where she serves as the vice
chair of the compliance committee. She is also a member of the
Philadelphia Forum of Executive Women and a former member and chair
of the board of directors for the Public Interest Law Center. Ms.
Knight has an undergraduate degree in accounting from the
University of Virginia and holds an MBA in finance and strategic
management from the Wharton School, University of Pennsylvania. Ms.
Knight is a certified public accountant licensed in
Pennsylvania.
About Integra LifeSciences
At Integra LifeSciences, we are driven by our purpose of
restoring patients’ lives. We innovate treatment pathways to
advance patient outcomes and set new standards of surgical,
neurologic and regenerative care. We offer a comprehensive
portfolio of high quality, leadership brands that include
AmnioExcel®, Aurora®, Bactiseal®, BioD™, CerebroFlo®, CereLink®
Certas® Plus, Codman®, CUSA®, Cytal®, DuraGen®, DuraSeal®,
DuraSorb®, Gentrix®, ICP Express®, Integra®, Licox®, MAYFIELD®,
MediHoney®, MicroFrance®, MicroMatrix®, NeuraGen®, NeuraWrap™,
PriMatrix®, SurgiMend®, TCC-EZ® and VersaTru®. For the latest news
and information about Integra and its products, please visit
www.integralife.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties and reflect the Company's
judgment as of the date of this release. All statements, other than
statements of historical fact, are statements that could be deemed
forward-looking statements. These forward-looking statements relate
to, among other things, expectations, estimates and projections
concerning the Company’s business and operations, financial
performance, strategic initiatives and product development. Such
forward-looking statements involve risks and uncertainties that
could cause actual results to differ from predicted results. These
risks and uncertainties include, without limitation, the ability of
the Company to successfully manage leadership changes, other
factors beyond the Company's control and the economic, competitive,
governmental, technological, and other factors identified under the
heading "Risk Factors" included in item 1A of Integra's Annual
Report on Form 10-K for the year ended December 31, 2022, and
information contained in subsequent filings with the Securities and
Exchange Commission. These forward-looking statements are made only
as the date thereof, and the Company undertakes no obligation to
update or revise the forward-looking statements, whether as a
result of new information, future events or otherwise.
CONTACT: Integra LifeSciences Holdings
Corporation
Investor Relations:Chris Ward(609)
772-7736chris.ward@integralife.com
Media Contact:Laurene Isip(609)
208-8121laurene.isip@integralife.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/b2577940-1703-44ed-b943-0056e7afe134
Integra LifeSciences (NASDAQ:IART)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Integra LifeSciences (NASDAQ:IART)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024